By Nick Johnson (Apyx) In 2023 Shareholder News, RenuvionPosted February 1, 2023APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF THE RENUVION APR HANDPIECE FOR THE COAGULATION OF SUBCUTANEOUS SOFT TISSUES WHERE NEEDED, FOLLOWING LIPOSUCTION READ MORE
By apyxmedical In 2023 Shareholder News, RenuvionPosted January 25, 2023APYX MEDICAL CORPORATION LAUNCHES NEW ‘APYX ONE CONSOLE’ FOR COSMETIC SURGICAL PROCEDURES IN THE UNITED STATES READ MORE
By apyxmedical In 2022 Shareholder News, 2023 Shareholder News, J-Plasma, RenuvionPosted January 10, 2023APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 REVENUE RESULTS READ MORE
By apyxmedical In 2023 Shareholder News, J-Plasma, RenuvionPosted January 3, 2023APYX MEDICAL CORPORATION EMBARKS ON INAUGURAL BRAND CAMPAIGN FOR RENUVION READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted November 22, 2022APYX MEDICAL CORPORATION TO PARTICIPATE IN THE PIPER SANDLER 34TH ANNUAL HEALTHCARE CONFERENCE READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted November 10, 2022APYX MEDICAL CORPORATION REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOK READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted September 26, 2022APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON NOVEMBER 10, 2022 READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted September 13, 2022‘BOTCHED’ TV STAR DR. PAUL NASSIF AMONG TOP U.S. PLASTIC SURGEONS USING RENUVION HELIUM PLASMA TECHNOLOGY IN COSMETIC PROCEDURES READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted September 6, 2022APYX MEDICAL CORPORATION TO PARTICIPATE IN THE LAKE STREET BEST IDEAS GROWTH CONFERENCE READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted August 11, 2022APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOK READ MORE
